Cited by 3,448Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and ManagementMelanoma and MAPK Pathways

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Open access

Hugo, Willy, Zaretsky, Jesse M., Sun, Lu, Song, Chunying, Moreno, Blanca Homet, Hu-Lieskovan, Siwen, Berent-Maoz, Beata, Pang, Jia, Chmielowski, Bartosz, Cherry, Grace, Seja, Elizabeth, Lomeli, Shirley, Kong, Xiangju, Kelley, Mark C., Sosman, Jeffrey A., Johnson, Douglas B., Ribas, Antoni, Lo, Roger S.·2016·Cell

DOI 10.1016/j.cell.2016.02.065PMC PMC4808437

Open this paper in CoChat — free account Open PDF

Abstract

PD-1 immune checkpoint blockade provides significant clinical benefits for melanoma patients. We analyzed the somatic mutanomes and transcriptomes of pretreatment melanoma biopsies to identify factors that may influence innate sensitivity or resistance to anti-PD-1 therapy. We find that overall high mutational loads associate with improved survival, and tumors from responding patients are enriched for mutations in the DNA repair gene BRCA2. Innately resistant tumors display a transcriptional signature (referred to as the IPRES, or innate anti-PD-1 resistance), indicating concurrent up-expression of genes involved in the regulation of mesenchymal transition, cell adhesion, extracellular matrix remodeling, angiogenesis, and wound healing. Notably, mitogen-activated protein kinase (MAPK)-targeted therapy (MAPK inhibitor) induces similar signatures in melanoma, suggesting that a non-genomic form of MAPK inhibitor resistance mediates cross-resistance to anti-PD-1 therapy. Validation of the IPRES in other independent tumor cohorts defines a transcriptomic subset across distinct types of advanced cancer. These findings suggest that attenuating the biological processes that underlie IPRES may improve anti-PD-1 response in melanoma and other cancer types.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2016.02.065

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn923 · Cited by 14,108
TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions.
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks
Trapnell, C., Roberts, A., Goff, L. A., Pertea, G. M., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,145
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499

Flagged first, then by citations

Show all 46 references

Sorted by citations

Items 701–800 of 1,009

ULK1-ATG13 and their mitotic phospho-regulation by CDK1 connect autophagy to cell cycle
Li, Z., Tian, X., Ji, X., Wang, J., Chen, H., Wang, D., & Zhang, X. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000288 · Cited by 59
Multi‐omics analysis of disulfidptosis regulators and therapeutic potential reveals glycogen synthase 1 as a disulfidptosis triggering target for triple‐negative breast cancer
Xie, J., Deng, X., Xie, Y., Zhu, H., Liu, P., Deng, W., Ning, L., Tang, Y., Sun, Y., Tang, H., et al. (2024) · MedComm · doi:10.1002/mco2.502 · Cited by 75
Integrative molecular and spatial analysis reveals evolutionary dynamics and tumor-immune interplay of in situ and invasive acral melanoma
Liu, H., Gao, J.-W., Feng, M., Cheng, J., Tang, Y., Cao, Q., Zhao, Z., Meng, Z., Zhang, J., Zhang, G., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.012 · Cited by 75
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
Jessurun, C. A. C., Vos, J. A. M., Limpens, J., & Luiten, R. M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00233 · Cited by 76
Learning from PD-1 Resistance: New Combination Strategies
Bu, X., Mahoney, K. M., & Freeman, G. J. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.04.008 · Cited by 74
Neoantigens encoded in the cancer genome
Schumacher, T. N., & Hacohen, N. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.07.005 · Cited by 74
Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination
Guillebon, É. D., Dardenne, A., Saldmann, A., Séguier, S., Tran, T., Paolini, L., Lebbé, C., & Tartour, É. (2020) · International Journal of Cancer · doi:10.1002/ijc.32889 · Cited by 76
In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma
Babačić, H., Lehtiö, J., de Coaña, Y. P., Pernemalm, M., & Eriksson, H. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000204 · Cited by 72
Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy
Schetters, S. T. T., Rodríguez, E., Kruijssen, L. J. W., Crommentuijn, M. H. W., Boon, L., den Bossche, J. V., den Haan, J. M. M., & van Kooyk, Y. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000588 · Cited by 79
Immune infiltration profiling in gastric cancer and their clinical implications
Ren, F., Zhao, Q., Zhao, M., Shaogong, Z., Liu, B., Bukhari, I., Zhang, K., Wu, W., Fu, Y., Yu, Y., et al. (2021) · Cancer Science · doi:10.1111/cas.15057 · Cited by 73
Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor–Induced Synthetic Lethality
Kornepati, A. V. R., Boyd, J. T., Murray, C. E., Saifetiarova, J., Avalos, B. D. L. P., Rogers, C. M., Bai, H., Padron, A. S., Liao, Y., Ontiveros, C. O., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2076 · Cited by 73
Liquid biopsies to occult brain metastasis
Rehman, A. U., Κhan, P., Maurya, S. K., Siddiqui, J. A., Santamaria‐Barria, J. A., Batra, S. K., & Nasser, M. W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01577-x · Cited by 72
Computational immunogenomic approaches to predict response to cancer immunotherapies
Addala, V., Newell, F., Pearson, J. V., Redwood, A., Robinson, B. W. S., Creaney, J., & Waddell, N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00830-6 · Cited by 79
Immune checkpoint inhibitors: new strategies to checkmate cancer
Wilson, R., Evans, T. R. J., Fraser, A. R., & Nibbs, R. J. B. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.13081 · Cited by 72
Computational immune profiling in lung adenocarcinoma reveals reproducible prognostic associations with implications for immunotherapy
Varn, F. S., Tafe, L. J., Amos, C. I., & Cheng, C. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1431084 · Cited by 70
Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade
Boshuizen, J., Pencheva, N., Krijgsman, O., Altimari, D. M. D., Castro, P. G., de Bruijn, B., Ligtenberg, M. A., den Heuvel, E. G.-V., Vredevoogd, D. W., Song, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-0434 · Cited by 73
Arginine Metabolism and Its Potential in Treatment of Colorectal Cancer
Du, T., & Han, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.658861 · Cited by 72
PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade
Srour, N., Villarreal, O. D., Hardikar, S., Yu, Z., Preston, S. E. J., Miller, W. H., Szewczyk, M. M., Baršytė-Lovejoy, D., Xu, H., Chen, T., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110582 · Cited by 70
Single-cell N6-methyladenosine regulator patterns guide intercellular communication of tumor microenvironment that contribute to colorectal cancer progression and immunotherapy
Gao, Y., Wang, H., Chen, S., An, R., Chu, Y., Li, G., Wang, Y., Xie, X., & Zhang, J. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03395-7 · Cited by 71
Identification of CircRNA signature associated with tumor immune infiltration to predict therapeutic efficacy of immunotherapy
Dong, Y., Gao, Q., Chen, Y., Zhang, Z., Du, Y., Liu, Y., Zhang, G., Li, S., Wang, G., Chen, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38232-y · Cited by 71
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Pavlick, A. C., Ariyan, C. E., Buchbinder, E. I., Davar, D., Gibney, G. T., Hamid, O., Hieken, T. J., Izar, B., Johnson, D. B., Kulkarni, R. P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006947 · Cited by 74
Self-citation
Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk, promoting immunosuppression and immunotherapy resistance
Scolaro, T., Manco, M., Pecqueux, M., Amorim, R., Trotta, R., Acker, H. H. V., Haele, M. V., Shirgaonkar, N., Naulaerts, S., Daniluk, J., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00771-8 · Cited by 77
Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapy
Chhabra, Y., Fane, M. E., Pramod, S., Hüser, L., Zabransky, D. J., Wang, V., Dixit, A., Zhao, R., Kumah, E., Brezka, M. L., et al. (2024) · Cell · doi:10.1016/j.cell.2024.08.013 · Cited by 74
Evolution of MHC-based technologies used for detection of antigen-responsive T cells
Bentzen, A. K., & Hadrup, S. R. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1971-5 · Cited by 71
A Blueprint to Advance Colorectal Cancer Immunotherapies
Le, D. T., Hubbard-Lucey, V. M., Morse, M. A., Heery, C. R., Dwyer, A. J., Marsilje, T. H., Brodsky, A. N., Chan, E. W., Deming, D. A., Diaz, L. A., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0375 · Cited by 71
Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma
Fattore, L., Ruggiero, C. F., Pisanu, M. E., Liguoro, D., Cerri, A., Costantini, S., Capone, F., Acunzo, M., Romano, G., Nigita, G., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0205-5 · Cited by 69
Role of CXCR3 signaling in response to anti-PD-1 therapy
Han, X., Wang, Y., Sun, J., Tan, T., Cai, X., Lin, P., Tan, Y., Zheng, B., Wang, B., Wang, J., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.067 · Cited by 71
Role of DNA repair defects in predicting immunotherapy response
Zhang, J., Shih, D. J. H., & Lin, S. (2020) · Biomarker Research · doi:10.1186/s40364-020-00202-7 · Cited by 70
Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target
Wang, H., Zhou, Y., Zhang, Y., Fang, S., Zhang, M., Li, H., Xu, F., Liu, L., Liu, J., Zhao, Q., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004302 · Cited by 69
CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas
Niborski, L. L., Gueguen, P., Ye, M., Thiolat, A., Ramos, R. N., Caudana, P., Denizeau, J., Colombeau, L., Rodriguez, R., Goudot, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31504-z · Cited by 70
An artificial intelligence network‐guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms
Zhang, N., Zhang, H., Liu, Z., Dai, Z., Wu, W., Zhou, R., Li, S., Wang, Z., Liang, X., Wen, J., et al. (2023) · Cell Proliferation · doi:10.1111/cpr.13409 · Cited by 71
Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies
Pulanco, M. C., Madsen, A. T., Tanwar, A., Corrigan, D. T., & Zang, X. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01019-8 · Cited by 69
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Wang, S. L., & Chan, T. A.-T. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.006 · Cited by 80
Investigating the utility of human melanoma cell lines as tumour models
Vincent, K. M., & Postovit, L.-M. M. (2017) · Oncotarget · doi:10.18632/oncotarget.14443 · Cited by 70
CloudNeo: a cloud pipeline for identifying patient-specific tumor neoantigens
Bais, P., Namburi, S., Gatti, D. M., Zhang, X., & Chuang, J. H. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx375 · Cited by 69
The Tumor Microenvironment in Colorectal Cancer Therapy
Pedrosa, L., Esposito, F. M., Thomson, T. M., & Maurel, J. (2019) · Cancers · doi:10.3390/cancers11081172 · Cited by 73
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype
Jaiswal, A. R., Liu, A. J., Pudakalakatti, S., Dutta, P., Jayaprakash, P., Bartkowiak, T., Ager, C. R., Wang, Z., Reuben, A., Cooper, Z. A., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0005 · Cited by 71
Unique Photochemo-Immuno-Nanoplatform against Orthotopic Xenograft Oral Cancer and Metastatic Syngeneic Breast Cancer
Zhang, L., Jing, D., Wang, L., Sun, Y., Li, J. J., Hill-Payne, B., Yang, F., Li, Y., & Lam, K. S. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b03096 · Cited by 68
Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
Zemek, R. M., Chin, W. L., Nowak, A. K., Millward, M., Lake, R., & Lesterhuis, W. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00223 · Cited by 73
Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses
Groeneveldt, C., van Hall, T., van der Burg, S. H., ten Dijke, P., & van Montfoort, N. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.003 · Cited by 68
A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response
Hakimi, A. A., Attalla, K., DiNatale, R. G., Ostrovnaya, I., Flynn, J. R., Blum, K. A., Ged, Y. M. A., Hoen, D. R., Kendall, S. M., Reznik, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17965-0 · Cited by 68
Cancer-Associated Fibroblasts and T Cells: From Mechanisms to Outcomes
Baker, A. T., Abuwarwar, M. H., Poly, L., Wilkins, S., & Fletcher, A. L. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001203 · Cited by 72
TGF-β in Cancer: Metabolic Driver of the Tolerogenic Crosstalk in the Tumor Microenvironment
Angioni, R., Sánchez‐Rodríguez, R., Viola, A., & Molon, B. (2021) · Cancers · doi:10.3390/cancers13030401 · Cited by 73
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
Shklovskaya, E., & Rizos, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136741 · Cited by 71
A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype
Chen, Z., Wang, M., Wilde, R. L. D., Feng, R., Su, M., la Roche, L. A. T.-D., & Shi, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.749459 · Cited by 70
Lactylation‐Driven NUPR1 Promotes Immunosuppression of Tumor‐Infiltrating Macrophages in Hepatocellular Carcinoma
Cai, J., Zhang, P., Cai, Y., Zhu, G., Chen, S., Song, L., Du, J.-X., Wang, B., Dai, W., Zhou, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202413095 · Cited by 75
The Landscape of Tumor Fusion Neoantigens: A Pan-Cancer Analysis
Wei, Z., Zhou, C., Zhang, Z., Guan, M., Zhang, C., Liu, Z., & Liu, Q. (2019) · iScience · doi:10.1016/j.isci.2019.10.028 · Cited by 67
Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
van Wilpe, S., Tolmeijer, S. H., Koornstra, R. H. T., de Vries, I. J. M., Gerritsen, W. R., Ligtenberg, M. J. L., & Mehra, N. (2021) · Cancers · doi:10.3390/cancers13092249 · Cited by 67
Profiling Cancer-Associated Fibroblasts in Melanoma
Papaccio, F., Kovacs, D., Bellei, B., Caputo, S., Migliano, E., Cota, C., & Picardo, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147255 · Cited by 67
Oncogenic CDK13 mutations impede nuclear RNA surveillance
Insco, M. L., Abraham, B. J., Dubbury, S. J., Kaltheuner, I. H., Dust, S., Wu, C., Chen, K. Y., Liu, D., Bellaousov, S., Cox, A. M., et al. (2023) · Science · doi:10.1126/science.abn7625 · Cited by 66
Histone modifications in drug-resistant cancers: From a cancer stem cell and immune evasion perspective
Jin, M. L., & Jeong, K. W. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01014-z · Cited by 69
Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy
Matsumoto, M., Takeda, Y., Tatematsu, M., & Seya, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01897 · Cited by 67
The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape
Vanni, I., Tanda, E. T., Spagnolo, F., Andreotti, V., Bruno, W., & Ghiorzo, P. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00113 · Cited by 69
Suppression of tumor antigen presentation during aneuploid tumor evolution contributes to immune evasion
Tripathi, R., Modur, V., Senovilla, L., Kroemer, G., & Komurov, K. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1657374 · Cited by 66
Using DNA sequencing data to quantify T cell fraction and therapy response
Bentham, R. B., Litchfield, K., Watkins, T. B. K., Lim, E. L., Rosenthal, R., Martínez‐Ruiz, C., Hiley, C. T., Bakir, M. A., Salgado, R., Moore, D. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03894-5 · Cited by 63
Epigenetic modulation in cancer immunotherapy
Gallagher, S. J., Shklovskaya, E., & Hersey, P. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.006 · Cited by 68
Melanoma Immunotherapy: Next-Generation Biomarkers
Hogan, S. A., Levesque, M. P., & Cheng, P. F. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00178 · Cited by 68
The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma
Chen, H., Yang, M., Wang, Q., Song, F., Li, X., & Chen, K. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1608132 · Cited by 66
Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma
Kümpers, C., Jokić, M., Haase, O., Offermann, A., Vogel, W., Grätz, V., Langan, E. A., Perner, S., & Terheyden, P. A. M. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00027 · Cited by 65
Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy
Shklovskaya, E., & Rizos, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197139 · Cited by 64
Identification of gastric cancer subtypes based on pathway clustering
Li, L., & Wang, X. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00186-z · Cited by 64
Integrated analyses of m 1 A regulator-mediated modification patterns in tumor microenvironment-infiltrating immune cells in colon cancer
Gao, Y., Wang, H., Li, H., Ye, X., Xia, Y., Yuan, S., Lu, J., Xie, X., Wang, L., & Zhang, J. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1936758 · Cited by 66
Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 Therapy
Dousset, L., Poizeau, F., Robert, C., Mansard, S., Mortier, L., Caumont, C., Routier, É., Dupuy, A., Rouanet, J., Battistella, M., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00084 · Cited by 71
Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy
Chida, K., Kawazoe, A., Suzuki, T., Kawazu, M., Ueno, T., Takenouchi, K., Nakamura, Y., Kuboki, Y., Kotani, D., Kojima, T., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0041 · Cited by 66
Immune-resistant mechanisms in cancer immunotherapy
Kawakami, Y., Ohta, S., Sayem, M. A., Tsukamoto, N., & Yaguchi, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01611-x · Cited by 65
Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab Treatment
Qu, Y., Wen, J., Thomas, G. D., Yang, W., Prior, W., He, W., Sundar, P. D., Wang, X., Potluri, S., & Salek‐Ardakani, S. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107873 · Cited by 67
Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma
Adhikaree, J., Moreno-Vicente, J., Kaur, A. P., Jackson, A. M., & Patel, P. M. (2020) · Cells · doi:10.3390/cells9020263 · Cited by 68
Intratumoral hypoxia and mechanisms of immune evasion mediated by hypoxia-inducible factors
Semenza, G. L. (2021) · Physiology · doi:10.1152/physiol.00034.2020 · Cited by 64
Cancer-associated fibroblasts are the main contributors to epithelial-to-mesenchymal signatures in the tumor microenvironment
Szabó, P. M., Vajdi, A., Kumar, N., Tolstorukov, M. Y., Chen, B. J., Edwards, R. H., Ligon, K. L., Chasalow, S. D., Chow, K.-H., Shetty, A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-28480-9 · Cited by 71
In the Wnt-er of life: Wnt signalling in melanoma and ageing
Kaur, A., Webster, M. R., & Weeraratna, A. T. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.332 · Cited by 64
Strategies for developing and optimizing cancer vaccines
Maeng, H. M., & Berzofsky, J. A. (2019) · F1000Research · doi:10.12688/f1000research.18693.1 · Cited by 65
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
Hegde, A. M., Jayaprakash, P., Couillault, C., Piha-Paul, S. A., Karp, D. D., Rodon, J. A., Pant, S., Fu, S., Dumbrava, E. E. I., Yap, T. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4118 · Cited by 62
Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy
Amato, C. M., Hintzsche, J. D., Wells, K. R., Applegate, A. J., Gorden, N. T., Vorwald, V. M., Tobin, R. P., Nassar, K. W., Shellman, Y. G., Kim, J., et al. (2020) · Cancers · doi:10.3390/cancers12071943 · Cited by 63
m 6 A modification patterns and tumor immune landscape in clear cell renal carcinoma
Zhong, J., Liu, Z., Cai, C., Duan, X., Deng, T., & Zeng, G. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001646 · Cited by 64
Selective modulation by PARP-1 of HIF-1α-recruitment to chromatin during hypoxia is required for tumor adaptation to hypoxic conditions
Martí, J. M., García-Díaz, Á., Delgado‐Bellido, D., O’Valle, F., González-Flores, A., Carlevaris, O., Rodríguez-Vargas, J. M., Amé, J., Dantzer, F., King, G. L., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101885 · Cited by 64
Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses
Huang, F., Gonçalves, C., Bartish, M., Rémy-Sarrazin, J., Issa, M. E., Cordeiro, B., Guo, Q., Émond, A., Attias, M., Yang, W., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140752 · Cited by 63
Polo-Like Kinase 4’s Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy
Zhang, X., Wei, C., Liang, H., & Han, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.587554 · Cited by 61
Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy
Huang, F., Santinon, F., González, R. E. F., & Rincon, S. V. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.756001 · Cited by 66
Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study
Liu, R., Yang, F., Yin, J., Liu, Y., Zhang, W., & Zhou, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.685370 · Cited by 62
CD20+CD22+ADAM28+ B Cells in Tertiary Lymphoid Structures Promote Immunotherapy Response
Wu, Z., Zhou, J., Xiao, Y., Ming, J., Zhou, J., Dong, F., Zhou, X., Xu, Z., Zhao, X., Lei, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.865596 · Cited by 65
Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
Hiltbrunner, S., Cords, L., Kasser, S., Freiberger, S. N., Kreutzer, S., Toussaint, N. C., Grob, L., Opitz, I., Messerli, M., Zoche, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40745-5 · Cited by 78
PD-1 defines a distinct, functional, tissue-adapted state in Vδ1+ T cells with implications for cancer immunotherapy
Davies, D., Kamdar, S., Woolf, R., Zlatareva, I., Iannitto, M. L., Morton, C., Haque, Y., Martin, H., Biswas, D., Ndagire, S., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00690-0 · Cited by 67
Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming
Yu, T., Liu, Z., Tao, Q., Xu, X., Li, X., Li, Y., Chen, M., Liu, R., Chen, D., Wu, M., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216824 · Cited by 65
Small-Molecule Targets in Immuno-Oncology
Dhanak, D., Edwards, J. P., Nguyen, A., & Tummino, P. J. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.019 · Cited by 65
Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens
Kiyotani, K., Chan, T., & Nakamura, Y. (2017) · Cancer Science · doi:10.1111/cas.13498 · Cited by 61
Treatment resistance in urothelial carcinoma: an evolutionary perspective
Vlachostergios, P. J., & Faltas, B. M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0026-y · Cited by 62
Contribution of Epithelial Plasticity to Therapy Resistance
Santamaría, P. G., Moreno‐Bueno, G., & Cano, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050676 · Cited by 66
Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications
Sun, W., Zhang, Q., Wang, R., Yang, L., Sun, Y., & Yang, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648687 · Cited by 62
NOTCH3 is a Prognostic Factor and Is Correlated With Immune Tolerance in Gastric Cancer
Cui, Y., Li, Q., Li, W., Wang, Y., Lv, F., Shi, X., Tang, Z., Shen, Z., Hou, Y., Zhang, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.574937 · Cited by 62
Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma
Liu, J., Shen, H., Gu, W., Zheng, H., Wang, Y., Ma, G., & Du, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.960738 · Cited by 61
Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
Shoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jaderberg, M. E. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2046 · Cited by 62
The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression
Ahn, R., Sabourin, V., Bolt, A. M., Hébert, S., Totten, S., Jay, N. D., Festa, M. C., Young, Y. K., Im, Y. K., Pawson, T. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14638 · Cited by 64
Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors
Dammeijer, F. F., Lau, S. P., van Eijck, C. H. J., van der Burg, S. H., & Aerts, J. G. J. V. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.011 · Cited by 66
Liposome-based immunity-inducing systems for cancer immunotherapy
Yuba, E. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.11.001 · Cited by 63
Immune profiling of microsatellite instability-high and polymerase ε (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy
Wang, C., Gong, J., Tu, T. Y., Lee, P. P., & Fakih, M. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.01.09 · Cited by 62
Personalized cancer neoantigen vaccines come of age
Chu, Y., Liu, Q., Wei, J., & Liu, B. (2018) · Theranostics · doi:10.7150/thno.24387 · Cited by 63
Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma
Yusko, E. C., Vignali, M., Wilson, R. K., Mardis, E. R., Hodi, F. S., Horak, C. E., Chang, H., Woods, D. M., Robins, H. S., & Weber, J. S. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0226 · Cited by 59
Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?
Castet, F., García‐Mulero, S., Pamplona, R. S., Cuellar, A., Casanovas, O., Mitjana, J. M. C., & Piulats, J. M. (2019) · Cancers · doi:10.3390/cancers11060834 · Cited by 64
EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma
Tiffen, J. C., Gallagher, S. J., Filipp, F. V., Gunatilake, D., Emran, A. A., Cullinane, C. M., Dutton‐Regester, K., Aoude, L. G., Hayward, N. K., Chatterjee, A., et al. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.02.042 · Cited by 64
Mutation load estimation model as a predictor of the response to cancer immunotherapy
Lyu, G.-Y., Yeh, Y.-H., Yeh, Y., & Wang, Y. (2018) · npj Genomic Medicine · doi:10.1038/s41525-018-0051-x · Cited by 60

Authors: Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., Seja, E., Lomeli, S., Kong, X., Kelley, M. C., Sosman, J. A., Johnson, D. B., Ribas, A., & Lo, R. S.
Affiliations: University of California, Los Angeles (US)
Vanderbilt University (US)
Corresponding author: Lo, Roger S.
ORCID: Hugo, Willy
Zaretsky, Jesse M.
Sun, Lu
Moreno, Blanca Homet
Berent-Maoz, Beata
Pang, Jia
Chmielowski, Bartosz
Lomeli, Shirley
Sosman, Jeffrey A.
Johnson, Douglas B.
Ribas, Antoni
Lo, Roger S.
Venue: Cell
Publisher: Elsevier BV
Published: 2016-03
Volume: 165
Issue: 1
Pages: 35-44
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2016.02.065
PMC: PMC4808437
OpenAlex: W2299181842
Cited by: 3,448
References: 46
Citations by year: 2026: 175 · 2025: 281 · 2024: 370 · 2023: 409 · 2022: 478 · 2021: 461 · 2020: 406 · 2019: 316 · 2018: 268 · 2017: 205 · 2016: 70
FWCI: 153.57
Type: journal article
Language: en
Update notices: erratum (2017-01-26)
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 388 d)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Institutes of Health (UL1TR000124)
National Cancer Institute (P01CA168585, K12 CA 0906525, K12CA090625, R35CA197633, P30CA016042, R01CA176111)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords: metastatic melanoma, anti-PD-1 therapy, immune checkpoint blockade, treatment response prediction, BRCA2 mutation, non-specific immunity, mesenchymal transition, extracellular matrix remodeling, angiogenesis, MAPK inhibitor resistance, cross-resistance, tumor transcriptome
MeSH terms: Nivolumab, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Melanoma, Neoplasm Metastasis, Drug Resistance, Neoplasm, MAP Kinase Signaling System, BRCA2 Protein, Transcriptome, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks